Boston Scientific, a leading medical technology company, has recently received expanded clearance from the U.S. Food and Drug Administration (FDA) for its cryoablation system. This clearance allows the company to market and sell its system for the treatment of atrial fibrillation (AF), a common heart rhythm disorder.
Atrial fibrillation affects millions of people worldwide and is characterized by an irregular and often rapid heartbeat. It can lead to various complications, including blood clots, stroke, and heart failure. Cryoablation is a minimally invasive procedure that uses extreme cold to create scar tissue in the heart, which disrupts the abnormal electrical signals causing AF.
Boston Scientific’s cryoablation system, known as the “HeartLogic™ System,” combines advanced mapping technology with a balloon-based catheter to deliver precise and controlled cooling to the heart tissue. The system uses nitrous oxide, a cryogenic gas, to rapidly freeze the targeted area, creating lesions that interrupt the abnormal electrical pathways responsible for AF.
The expanded FDA clearance allows Boston Scientific to market the cryoablation system for patients with persistent AF, a subtype of AF that is more challenging to treat. Previously, the system was only approved for patients with paroxysmal AF, which is characterized by intermittent episodes of irregular heartbeat.
The approval was based on data from a clinical trial called STOP AF First, which demonstrated the safety and effectiveness of the cryoablation system in treating persistent AF. The trial involved 203 patients who were randomly assigned to receive either cryoablation or drug therapy. The results showed that patients who underwent cryoablation had a significantly higher rate of freedom from AF compared to those on drug therapy.
Dr. Kenneth Stein, Chief Medical Officer of Boston Scientific’s Rhythm Management division, expressed his excitement about the expanded clearance, stating that it provides physicians with a valuable tool to help their patients with persistent AF. He also highlighted the potential benefits of cryoablation, such as reducing the need for long-term medication and improving patients’ quality of life.
The cryoablation system is part of Boston Scientific’s broader portfolio of solutions for the treatment of cardiac arrhythmias. The company is committed to developing innovative technologies that address unmet needs in the field of electrophysiology, which focuses on the diagnosis and treatment of heart rhythm disorders.
In addition to its expanded FDA clearance, Boston Scientific’s cryoablation system has also received CE Mark approval in Europe. This allows the company to market and sell the system in European countries, further expanding its reach and impact on patients with AF worldwide.
Overall, Boston Scientific’s cryoablation system receiving expanded FDA clearance is a significant development in the field of cardiac electrophysiology. It offers new hope for patients with persistent AF, providing them with a safe and effective treatment option that can improve their quality of life and reduce the risk of complications associated with this common heart rhythm disorder.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: Plato Data Intelligence.
- Source Link: https://platohealth.ai/boston-scientific-secures-expanded-fda-clearance-for-cryoablation-system/
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States The Food and...